STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Vitrolife (STO:VITR): A lung transplantation has for the first time been carried out using the STEEN Solution™ technology outside Sweden. Earlier on in the development and the first clinical use eight transplantations have been carried out using STEEN Solution™ at the University Hospital of Lund, where the technology was developed under the leadership of Professor Stig Steen. The method has now for the first time been used clinically somewhere else. “This is a breakthrough for the STEEN Solution™ technology, which shows that it is a practically useful clinical method that can be spread to the lung transplantation clinics of the world, thus benefiting those patients awaiting a lung transplantation, as the method has the potential to increase the number of organs available for transplantation,” says Magnus Nilsson, Vitrolife’s CEO.
